Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in moderate-to-severe atopic dermatitis
NCT05715320Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Countries
- 1
- Sponsor
- Keymed Biosciences
- Modality
- Monoclonal Antibodies
- Drugs
- stapokibart
- Conditions
- atopic dermatitis (AD)
01
Overview
Phase 2, randomised, double-blind trial of stapokibart in atopic dermatitis (AD) (2 arms), sponsored by Keymed Biosciences. Primary endpoint: Proportion of subjects achieving EASI-75 at 12 weeks. Started Mar 2023; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Group A
Stapokibart (CM310) subcutaneous
Group B
Stapokibart (CM310) subcutaneous
03
Who it enrols
Adults aged 18-75 with moderate-to-severe atopic dermatitis, agreeing to contraception. Exclusion includes recent live vaccines (within 12 weeks), allergen-specific immunotherapy (within 6 months), major planned surgery, atopic keratoconjunctivitis/corneal involvement, or allergy to IL-4Rα antibodies.
04
Endpoints
Primary
Proportion of subjects achieving EASI-75
Beyond the preview
Go deeper on NCT05715320.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715320.